Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris

Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris

Abstract is missing (Short communication)

Bibliographic Details
Main Authors:	Katharina Boch, Ewan A. Langan, Enno Schmidt, Detlef Zillikens, Ralf J. Ludwig, Katja Bieber, Christoph M. Hammers
Format:	Article
Language:	English
Published:	Medical Journals Sweden 2022-03-01
Series:	Acta Dermato-Venereologica
Subjects:	Pemphigus Rituximab Therapy Immunosuppression SARS-CoV2 COVID-19
Online Access:	https://medicaljournalssweden.se/actadv/article/view/907

Similar Items

Faster IgG4 Depletion Kinetics Observed for Anti-Desmoglein 3 Autoantibodies Following Rituximab Treatment in Patients with Pemphigus Vulgaris
by: Katharina Boch, et al.
Published: (2022-12-01)

Four cases of recalcitrant pemphigus vulgaris salvaged with rituximab
by: Samyak Ganjre, et al.
Published: (2017-01-01)

Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months
by: Kamran Balighi, et al.
Published: (2019-05-01)

Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report
by: Mohamad Y. Khatib, et al.
Published: (2021-02-01)

Real world evidence: Patients with refractory pemphigus treated with Rituximab
by: Vagiani Perifani, et al.
Published: (2021-12-01)

Management of pemphigus vulgaris with rituximab: A case report and brief review on emerging treatment options
by: Massillamani Francis, et al.
Published: (2019-01-01)

Efficacy and safety of biosimilar rituximab in the treatment of pemphigus vulgaris: a single center experience of 12 cases
by: Federico Bardazzi, et al.
Published: (2022-01-01)

Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil
by: Stephanie Del Rio Navarrete Biot, et al.
Published: (2014-12-01)

Rituximab treatment of pemphigus in women of childbearing age: experience with two patients
by: Eden P. Lake, et al.
Published: (2017-11-01)

Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia
by: Ben Koszegi, et al.
Published: (2023-03-01)

Pemphigus vulgaris with refractory gingival ulcerations, successfully treated with rituximab—A case report
by: Mateja Dolenc‐Voljč, et al.
Published: (2022-09-01)

Rituximab‐induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review
by: Leila Ghadirzade Arani, et al.
Published: (2024-03-01)

B-cell depletion in the treatment of pemphigus: two clinical cases and literature review
by: Oleg V. Karzanov, et al.
Published: (2023-02-01)

Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study
by: Roja Toosi, et al.
Published: (2021-01-01)

Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability
by: Ciolfi C, et al.
Published: (2022-11-01)

Rituximab/IVIG in pemphigus – a 10-year study with a long follow-up
by: Issam Hamadah, et al.
Published: (2019-02-01)

Rituximab for the treatment of pemphigus and pemphigoid: A case series of ten patients
by: Safaa S Alwaash, et al.
Published: (2019-01-01)

Pre-infusion checklist for rituximab in pemphigus vulgaris patients: clinical audit
by: Farah Sagheer, et al.
Published: (2023-07-01)

A modified regimen of rituximab in pemphigus: A retrospective study
by: Tanvi Pradeep Vaidya, et al.
Published: (2020-01-01)

A comparative study to evaluate the efficacy and cost of rituximab versus dexamethasone cyclophosphamide pulse in patients of pemphigus vulgaris
by: Sudip Das, et al.
Published: (2021-01-01)

Coexistance of Pemphigus Vulgaris and Psoriasis in a Middle Aged Man
by: Sara Saniee, et al.
Published: (2017-01-01)

Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?
by: Christian Ciolfi, et al.
Published: (2024-01-01)

The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study
by: Xingli Zhou, et al.
Published: (2024-12-01)

Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant
by: Giulio Fortuna, et al.
Published: (2021-11-01)

Therapeutic difficulties related to optimization of pemphigus vulgaris treatment
by: Szymon Leonik, et al.
Published: (2020-12-01)

Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients
by: Jordan M. Keeley, et al.
Published: (2019-05-01)

Severe Pemphigus Vulgaris Resistant to Conventional Therapies and with Hypersensitivity to Rituximab in a 12-Year-Old Child
by: Maria Beatrice De Felici Del Giudice, et al.
Published: (2023-05-01)

Successful treatment of recalcitrant juvenile pemphigus foliaceus with intravenous immunoglobulin and rituximab
by: Hock Gin Teo, et al.
Published: (2022-01-01)

Combination therapy for management of pemphigus patients with unexpected therapeutic response to rituximab: A report of five cases
by: Zeinab Aryanian, et al.
Published: (2023-11-01)

Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
by: Gabrielle Benesh, BS, et al.
Published: (2021-10-01)

Off-label use of rituximab in dermatology: pemphigus treatment
by: Lislaine Bomm, et al.
Published: (2013-08-01)

Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients
by: Ahreum Song, et al.
Published: (2022-08-01)

Anterior scleritis in pemphigus vulgaris: A rare ocular manifestation
by: Pradnya K Bhole, et al.
Published: (2022-01-01)

The positive impact of rituximab on the quality of life and mental health in patients with pemphigus
by: Hanan Rashid, MD, et al.
Published: (2022-06-01)

Rituximab Therapy for Treatment of Pemphigus in Southeast Asians
by: Kanokrungsee S, et al.
Published: (2021-04-01)

Case Report: Management of Malignancy-Exacerbated Pemphigus Vulgaris During COVID-19 Pandemic
by: Alberto Corrà, et al.
Published: (2021-08-01)

Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study
by: Joško Miše, et al.
Published: (2022-05-01)

Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus
by: Burçin Cansu Bozca, et al.
Published: (2022-05-01)

Current status and considerations on the diagnosis and treatment of pemphigus in China
by: PAN Meng, WANG Jingying
Published: (2023-06-01)

Cotrimoxazole as a Preventative Intervention for Pneumocystis Pneumonia in Pemphigus Patients Treated with Rituximab: A Retrospective Study
by: Hao-Chen Hsu, et al.
Published: (2023-06-01)